Ovarian cancer often goes undetected until it spreads to other areas. In its late stages, it's harder to treat. Now there's an unconventional treatment being used to get rid of it. When her stomach ...

Adding hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery significantly improved overall survival (OS) in women with platinum-sensitive, recurrent epithelial ovarian carcinoma, ...

Median progression-free survival (PFS) improved from 23 months with surgery alone to 25 months with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC), a nonsignificant difference. Post ...

HIPEC is a type of treatment for cancers that have spread within your abdomen. Doctors surgically remove the tumor and then pump heated chemotherapy drugs into your abdominal cavity. Hyperthermic ...

Cytoreductive surgery removes tumors that have spread throughout your abdominal cavity. It’s often combined with another procedure called hyperthermic intraperitoneal chemotherapy. You may need ...

A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator’s choice (IC) of chemotherapy in patients with platinum-resistant ovarian cancer (PROC). This is an ASCO ...

Amber and her family in the Volkswagen convertible she bought after learning she was cancer-free Amber used to live her life with anxiety and fear—always trying to stay within her comfort zone. She ...

SCS combined with HIPEC may improve overall survival in PSROC patients compared to SCS alone, with a statistically significant benefit observed. The risk of severe complications, including anemia and ...

Patients with advanced ovarian cancer undergoing interval cytoreductive surgery who received paclitaxel-based hyperthermic intraperitoneal chemotherapy (HIPEC) during surgery appeared to have ...

CRS-HIPEC stands for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. It’s pronounced “high-peck.” This treatment is for people with cancer that has spread to the lining of the ...

The expenditure of the Dutch health care system between 2017 and 2025 associated with the introduction of HIPEC for patients with stage III ovarian cancer eligible for interval CRS (target population) ...